Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
EAD therapy can shrink size of triple-negative breast cancer tumors in mice

EAD therapy can shrink size of triple-negative breast cancer tumors in mice

In a new study using mice and lab-grown human cells, a scientific team led by Johns Hopkins Kimmel Cancer Center researchers show how a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth. [More]
Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer. [More]
Researchers identify low MCJ expression as marker of poor response to chemotherapy

Researchers identify low MCJ expression as marker of poor response to chemotherapy

Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 (HER2). [More]
Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers. [More]
AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Prostate cancer is the second leading cause of mortality among American men with the highest incidence rate of all cancers reported in the U.S. Male sex hormones testosterone (T) and 5α-dihydrotestosterone (5α-DHT) promote prostate cancer progression. [More]
USP14 enzyme could be promising biomarker for detecting risk of endometrial cancer recurrences

USP14 enzyme could be promising biomarker for detecting risk of endometrial cancer recurrences

Endometrial cancer is the most common gynecologic cancer in the U.S. Most cases are diagnosed at early stage and have good prognosis. Unfortunately, some patients with early stage and low grade endometrial cancer experience recurrence - and the reasons are not entirely clear. [More]
Tecentriq drug gets FDA approval to treat urothelial carcinoma

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer. [More]
Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

The chemotherapy drug cisplatin can kill cancer, but it can also cause permanent hearing loss. [More]
Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information. [More]
Empowering mobile health: an interview with Dr Rich Khatib and Dan Vahdat

Empowering mobile health: an interview with Dr Rich Khatib and Dan Vahdat

overview of Medopad and how you deliver patient information to mobile devices?
Medopad is a mobile health technology company. We focus on developing software within the mobile health industry. Mobile health, from our perspective, is an industry that really was invented with the iPad. [More]
Research on immune system sets stage for novel approach to cancer immunotherapy

Research on immune system sets stage for novel approach to cancer immunotherapy

Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber Cancer Institute report in a new study in the Proceedings of the National Academy of Sciences. [More]
Novel therapeutic approach to treat leukaemia patients

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms. [More]
Experimental hepatitis C drug slows down development of Zika in mice

Experimental hepatitis C drug slows down development of Zika in mice

Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy. [More]
Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research. [More]
Arkin Holdings and Primera Capital lead investment of $13M in BioSight

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML. [More]

Texas to host first-ever delegation of UK’s medical technology companies

Texas is about to play host to the first ever delegation of innovative medical technology companies from the United Kingdom. [More]
Single breath-hold for more than five minutes could make targeted radiotherapy feasible

Single breath-hold for more than five minutes could make targeted radiotherapy feasible

Researchers at the University of Birmingham working with clinical teams at University Hospitals Birmingham NHS Foundation Trust have successfully shown for the first time that breast cancer patients can be trained to achieve single prolonged breath holds of over five minutes, opening the door for targeted radiotherapy to be administered with just one dose in each daily session. [More]
Mitoxantrone drug users more likely to develop colorectal cancer

Mitoxantrone drug users more likely to develop colorectal cancer

The multiple sclerosis (MS) drug mitoxantrone may be associated with an increased risk of colorectal cancer, according to a study published in the May 11, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. Mitoxantrone suppresses the immune system. [More]
University of Glasgow-led study could lead to improved treatments for lymphoma, other cancers

University of Glasgow-led study could lead to improved treatments for lymphoma, other cancers

A study by scientists at the University of Glasgow, which reveals the critical role a common cancer-associated gene plays in lymphoma development, could lead to improved treatments for a range of cancers. [More]
Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

From today, women in Scotland with an advanced and incurable form of cervical cancer could benefit from the targeted treatment Avastin, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS. [More]
Advertisement
Advertisement